Prostate CancerPhase 3NCT00273338
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
A Phase 3 study testing calcitriol and docetaxel in people with Prostate Cancer, run by Novacea at 222 sites in 9 countries.
Trial summary
The primary objective of this study is: To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- calcitriol and docetaxel
- How many people
- 1,200 participants
- Where
- 222 sitesin 9 countries
- Study dates
- Jan 2006to Nov 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histopathologically or cytologically proven adenocarcinoma of the prostate
- Documented metastatic prostate adenocarcinoma
- Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status <= 2
- Adequate hematologic, renal and hepatic function
- Life expectancy >= 3 months
Who cannot join
- Prior chemotherapy, except estramustine
- Prior chemotherapy with docetaxel
- Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)
- One or more contraindications to the use of corticosteroids
- History of cancer-related hypercalcemia
Trial locations and contacts
222 sites in 9 countries.
222 sites in 9 countries
United States159 sites
Pasco Hernando Oncology Associates, P.A.
14529 Cortez Blvd., Florida, 34613
Texas Cancer Center-Abilene
Abilene, Texas, 79606-5208
Phoebe Cancer Center
Albany, Georgia, 31701
Hematology Oncology Life Center
Alexandria, Louisiana, 71301
Texas Oncology, PA
Amarillo, Texas, 79106
Alaska Clinical Research Center
Anchorage, Alaska, 99508
Texas Cancer Center
Arlington, Texas, 76014
Urology Associates of North Texas (UANT)
Arlington, Texas, 76017
Northeast Georgia Cancer Care, LLC
Athens, Georgia, 30607
Peachtree Hematology-Oncology Consultants, PC
Atlanta, Georgia, 30309
Atlanta Cancer Care
Atlanta, Georgia, 30342
Texas Oncology Cancer Center
Austin, Texas, 78731
St. Agnes Health System
Baltimore, Maryland, 21229
MamieMcFaddin Ward Cancer Center
Beaumont, Texas, 77702-1449
Tower Cancer Research Foundation
Beverly Hills, California, 90211-1850
Birmingham Hematology & Oncology Associates, LLC
Birmingham, Alabama, 35223
SUNY Downstate Medical Center
Brooklyn, New York, 11203
Highline Medical Oncology
Burien, Washington, 98166
Aultman Hospital
Canton, Ohio, 44710
Gabrail Cancer Center
Canton, Ohio, 44718
Raleigh Hematology Oncology Associates
Cary, North Carolina, 27511
Iowa Cancer Care
Cedar Rapids, Iowa, 52403
Charleston Hematology Oncology PA
Charleston, South Carolina, 29403
Charleston Cancer Center
Charleston, South Carolina, 29406
Medical University Of South Carolina
Charleston, South Carolina, 29425
Chattanooga Oncology & Hematology Assoc.
Chattanooga, Tennessee, TN
Hematology Oncology Associates of Illinois
Chicago, Illinois, 60611
Midwest Prostate & Urology Health Center
Chicago, Illinois, 60640
Oncology Hematology Care, Inc.
Cincinnati, Ohio, 45242
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Rocky Mountain Cancer Centers
Colorado Springs, Colorado, 80909
Maryland Oncology Hematology, P.A.
Columbia, Maryland, 21044
Missouri Cancer Associates
Columbia, Missouri, 65201
University of Missouri, Ellis Fischel Cancer Center
Columbia, Missouri, 65203
Mid Ohio Oncology/Hematology, Inc.
Columbus, Ohio, 43213
Texas Cancer Center ar Medical City
Dallas, Texas, 75230-2510
Center for Oncology Research and Treatment, PA
Dallas, Texas, 75230
Texas Oncology, P.A.
Dallas, Texas, 75231-4400
The Texas Cancer Center
Dallas, Texas, 75237
North Broward Medical Center
Deerfield Beach, Florida, 33064
Henry Ford Health System
Detroit, Michigan, 48202
Consultants in Medical Oncology & Hematology
Drexel Hill, Pennsylvania, 19026
Hematology & Oncology Associates of Northeastern PA
Dunmore, Pennsylvania, 18512
Puget Sound Cancer Centers
Edmonds, Washington, 98026
El Paso Cancer Treatment Center-East
El Paso, Texas, 79915
Willamette Valley Cancer Center
Eugene, Oregon, 97401-8122
Fairfax Northern Virginia Hematology OnCology, PC
Fairfax, Virginia, 22031
Dakota Cancer Institute
Fargo, North Dakota, 58103
Carolina Cancer Management, Inc.
Fayetteville, North Carolina, 28304
Broward Oncology Associates
Fort Lauderdale, Florida, 33308
Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida, 33308
Florida Cancer Specialists
Fort Myers, Florida, 33901
Texas Oncology, P.A.
Fort Worth, Texas, 76104
The Center for Cancer & Blood Disorders
Fort Worth, Texas, 76104
Frederick Memorial Hospital
Frederick, Maryland, 21701
Gainesville Hematology Oncology Associates
Gainesville, Florida, 32605
University of Florida Shands Cancer Center
Gainesville, Florida, 32611
Northeast GA Medical Center
Gainesville, Georgia, 30501
Texas Oncology, P.A.
Garland, Texas, 75042-5788
The Jones Clinic
Germantown, Tennessee, 38138
Cancer Centers of the Carolina
Greenville, South Carolina, 29615
South Carolina Cancer Specialists
Hilton Head Island, South Carolina, 29926
Genesis Cancer Center
Hot Springs, Arkansas, 71913
Texas Oncology, P.A.
Houston, Texas, 77024
Central Indiana Cancer Centers
Indianapolis, Indiana, 46227
Integrated Community Oncology Network
Jacksonville, Florida, 32256
University of Kansas Medical Center
Kansas City, Kansas, 66160
Dayton Oncology & Hematology, P.A.
Kettering, Ohio, 45409
Medical Oncology Associates of Wyoming Valley, PC
Kingston, Pennsylvania, 18704
St. Mary Medical Center
Langhorne, Pennsylvania, 19047
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89109
Nevada Cancer Institute
Las Vegas, Nevada, 89135
Lake Vista Cancer Center
Lewisville, Texas, 75067
Nebraska Hematology-Oncology, PC
Lincoln, Nebraska, 68506
Pacific Shores Medical Group
Long Beach, California, 90813
Texas Oncology, P.A.
Longview, Texas, 75601
The Angeles Clinic and Research Institute, Inc.
Los Angeles, California, 90025
UCLA department of Urology
Los Angeles, California, 90095-1738
Southwest Cancer Treatment and Research Center
Lubbock, Texas, 79415
Veterans Affairs Northern California Health Care System
Martinez, California, 94553
Mercy Medical Center, North Iowa
Mason City, Iowa, 50401
South Texas Cancer Center - McAllen
McAllen, Texas, 78503
Texas Cancer Center of Mesquite
Mesquite, Texas, 75150
Sylvester Comprehensive Cancer Center, U of Miami
Miami, Florida, 33136
Allison Cancer Center
Midland, Texas, 79701-5946
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, 55404
MN Cooperative Group Outreach Prg.
Minneapolis, Minnesota, 55407
Sutter Gould Medical Foundation
Modesto, California, 95355
Monterey Bay Oncology
Monterey, California, 93940
Medical Consultants, PC c/o Ball Cancer Center
Muncie, Indiana, 47303
Northwest Alabama Cancer Center
Muscle Shoals, Alabama, 35661
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Cancer Care Network of South Texas, HOAST
New Braunfels, Texas, 78131
Hematology Oncology Associates of
New City, New York, 10956
Pasco Hernando Oncology Associates P.A.
New Port Richey, Florida, 34652
Florida Cancer Institute
New Port Richey, Florida, 34655
Memorial Sloan-Kett
New York, New York, 10021
UMDNJ-Newark
Newark, New Jersey, 07101
Cancer Care & Hematology Specialists of Chicagoland
Niles, Illinois, 60714
Virginia Oncology Associates
Norfolk, Virginia, 23502
Innovative Medical Research of South Florida Inc.
North Miami Beach, Florida, 33179
Ocala Oncology Center
Ocala, Florida, 34474
Cancer Centers of Florida, P.A.
Ocoee, Florida, 34761
West Texas Cancer Center
Odessa, Texas, 79761
University of Oklahoma
Oklahoma City, Oklahoma, 73104
Cancer Care Associates
Oklahoma City, Oklahoma, 73112
Nebraska Methodist Hospital - Oncology Research Dept
Omaha, Nebraska, 68144
Comprehensive Cancer Center at
Palm Springs, California, 92262
The Valley Hospital
Paramus, New Jersey, 07652
Paris Regional Cancer Center
Paris, Texas, 75460-5004
Oncology Specialists
Park Ridge, Illinois, 60068
Greater Philadelphia Cancer
Philadelphia, Pennsylvania, 19114
Hematology Associates - AOA
Phoenix, Arizona, 85012
Univeristy of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232
Pottsville Cancer Care
Pottsville, Pennsylvania, 17901
Interlakes Foundation Inc.
Rochester, New York, 14623
University of Rochester Medical Center
Rochester, New York, 14642
Swedish American Regional Cancer Center
Rockford, Illinois, 61104
Sutter Cancer Center
Sacramento, California, 95816
UCD Cancer Center-Clinical Trials
Sacramento, California, 95817
St. Joseph Oncology, Inc.
Saint Joseph, Missouri, 64507
Park Nicollet Institute
Saint Louis Park, Minnesota, 55416
Oncology & Hematology Associates of Southwest Virginia, Inc.
Salem, Virginia, 24153
South Texas Oncology and Hematology, PA
San Antonio, Texas, 78229
InVisions Consultants LLC
San Antonio, Texas, 78233
Sharp Memorial Hospital
San Diego, California, 92123
California Pacific Medical Center
San Francisco, California, 94115
New Mexico Cancer Care Associates
Sante Fe, New Mexico, 87505
Guthrie Clinic
Sayre, Pennsylvania, 18840
Maine Center for Cancer Medicine & Blood Disorders
Scarborough, Maine, 04074
Horizon's West Medical Group
Scottsbluff, Nebraska, 69361
Premiere Oncology of Arizona
Scottsdale, Arizona, 85260
University of Washington
Seattle, Washington, 98109
Puget Sound Cancer Centers
Seattle, Washington, 98133
Northern Arizona Hematology & Oncology Associates, AOA
Sedona, Arizona, 86336
Texas Cancer Center- Sherman
Sherman, Texas, 75090-0504
Siouxland Hematology-Oncology Associates
Sioux City, Iowa, 51101
Hematology Oncology Associates of Illinois, L.L.C
Skokie, Illinois, 60077
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46601
Stanford University
Stanford, California, 94305
Staten Island Urological Research, PC
Staten Island, New York, 10304
Texas Oncology Cancer Center-Sugar Land
Sugar Land, Texas, 77479
Overlook Oncology Center
Summit, New Jersey, 07901
Hope Center
Terre Haute, Indiana, 47802
AYS Urology
Trinity, Florida, 34655
Georgia Cancer Specialist
Tucker, Georgia, 30084
Southern Arizona VA Healthcare System
Tucson, Arizona, 85723
U of Arizona / Arizona Cancer Center
Tucson, Arizona, 85724
Cancer Care Associates
Tulsa, Oklahoma, 74136
South Georgia Medical Center
Valdosta, Georgia, 31602
Northwest Cancer Specialists, P.C.
Vancouver, Washington, 98684
Medical Center of Vincennes
Vincennes, Indiana, 47591
Texas Oncology
Waco, Texas, 76022
Texas Oncology Cancer Care and Research Center
Waco, Texas, 76712
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia, 20007
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801
Piedmont Hematology Oncology Associates, PLLC
Winston-Salem, North Carolina, 27103
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, 98902
Germany28 sites
Gemeinschaftspraxis für Hämatologie & Onkologie
Augsburg, 86150
Facharzt f. Urologie
Bad Schwartau, 23611
Urologische Praxis
Bautzen, 02625
Universitatsmedizin Charité
Berlin, 10117
Klinik am Urban
Berlin, 10967
Universitätsmedizin Charité Campus Benjamin Franklin
Berlin, 12200
Urologische Praxis
Berlin
Städtisches Klinikum Braunschweig
Braunschweig, 38126
Universitätsklinikum Köln
Cologne, 50931
Facharzt f. Urologie
Cottbus, 03046
Urologische Klinik
Dresden, 01307
Universitäsklinikum Düsseldorf
Düsseldorf, 40225
Urologische Klinik der Universitätsklink Düsseldorf
Düsseldorf, 40225
Universitätsklinikum Essen
Essen
Klinikum Fulda, Urologische Klinik
Fulda, 36043
Urologische Praxis
Hagenow
Urologische Gemeinschaftspraxis
Hamburg, 22399
Medizinische Hochschule Hannover
Hanover, 30625
Nationales Centrum für Tumorerkrankungen
Heidelberg, 69120
Universitätsklinikum Homburg/Saar
Homburg
Klinikum Kassel GmbH
Kassel, 34125
Gemeinschaftspraxis für Urologie
Kirchheim/Teck, 73230
Gesellschaft f. klinische Studien und Urologisches Gesundheitszentrum
Leipzig
Oberarzt d. Urolog. Abteilung
München, 81675
Obearzt der Urologischen Klinik, Universitätsklinik Münster
Münster, 48149
Praxisgemeinschaft für Onkologie und Urologie
Wilhelmshaven, 26389
Gemeinschaftspraxis f. Urologie
Wuppertal, 42103
Urologische Praxis
Zwickau
Canada18 sites
Tom Baker Cancer Center-Medical Oncology
Calgary, Alberta, T2N4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Regional Cancer Program de l'Hopital Regional de Sudbury
Greater Sudbury, Ontario, P3E 5J1
Centre for Clinical Research Cancer Care Program
Halifax, Nova Scotia, B3H 1V7
Jaravinski Cancer Centre Hamilton Health Services
Hamilton, Ontario, L8V 5C2
BCCA-Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
Cancer Centre of Southeastern Ontario
Kingston, Ontario, K7L 5P9
London Regional Cancer Program
London, Ontario, N6A 4L6
The Moncton Hospital (SERHA)
Moncton, New Brunswick, E1C 6Z8
Dr. Leon Richard Oncology Center
Moncton, New Brunswick, EIC8X3
McGill University
Montreal, Quebec, H2W 1S6
The Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, K1H 8L6
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, M4N 3M5
BCCA-Vancouver
Vancouver, British Columbia, V5Z4E6
British Columbia Cancer Agency - Vancouver Island Centre
Victoria, British Columbia, V8R 6V5
Windsor Regional Cancer Centre
Windsor, Ontario, N8W 2X3
Cancer Care Manitoba
Winnipeg, Manitoba, R3E0V9
Romania5 sites
Cabinetul de Urologie
Arad, 310175
Policlinica de diagnostic rapid
Brasov, 500366
Institutul Oncologic Bucuresti
Bucharest
Euro S.R.L.
Cluj-Napoca, 400046
ProVita 2000
Constanța, 900635
Hungary4 sites
IRM Center Hospital and Institutes, II.Department of Oncology
Budapest, 1071
Uzsoki Hospital of the Local Authority of Budapest, Oncoradiology
Budapest, H-1145
University of Debrecen, Medical and Health Science Center, Department of Oncology
Debrecen, H4032
University of Szeged, Szent-Györgyi Albert Medical and Pharmacist Science Center, Clinic of Oncotherapy
Szeged
Czechia3 sites
Institute of Radiation Oncology of Teaching Hospital Na Bulovce
Prague, 180 81
Department of Radiation and Oncology of Teaching Hospital Motol
Prague
Teaching Hospital Kralovske Vinohrady
Prague
Slovakia3 sites
Theaching Hospital of F.D. Roosevelt
Banská Bystrica, 97517
Faculty Hospital Martin
Martin, 03659
Faculty Hospital of J. A. Reiman
Prešov
Puerto Rico1 site
San Juan VA Medical Center, Reseach Dept
San Juan, 00921
Serbia and Montenegro1 site
Clinical Center Niš - Clinic of Urology
Belgrade, 18000
About this study
Official title: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
The primary objective of this study is:
- To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer
The secondary objectives of this study are:
- To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots)
- To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures)
- A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.
- Conditions
- Prostate Cancer
- Being tested
- calcitriol, docetaxel
- Keywords
- Androgen-independent Prostate Cancer (AIPC), Prostate Cancer, DN-101, calcitriol, Taxotere, docetaxel
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
calcitriolDrug
docetaxelDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2006 (estimated)
- Study startJan 2006
- Study completionNov 2007
Why it stopped: DSMB
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novacea
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Howard I. Scher, MD, Study chair, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer CenterKim N. Chi, M.D., Study chair, British Columbia Cancer Agency - Vancouver CentreRonald De-Wit, M.D., Study chair, Erasmus University Medical Center (Netherlands)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00273338
- Sponsor's protocol ID
- 011-007
- Status last verified
- Nov 2007
- First submitted
- 14 Dec 2005
- Last updated
- 6 Nov 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
- ClinicalTrials.gov ID
- NCT00273338
- Acronym / sponsor ID
- 011-007
- Conditions
- Prostate Cancer
- Keywords
- Androgen-independent Prostate Cancer (AIPC), Prostate Cancer, DN-101, calcitriol, Taxotere, docetaxel
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: DSMB
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- NovaceaIndustry (pharma, biotech, devices)
- Study start
- Jan 2006
- Study completion
- Nov 2007 (actual)
- First posted
- 9 Jan 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is:
- To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer
The secondary objectives of this study are:
- To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots)
- To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures)
- A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Histopathologically or cytologically proven adenocarcinoma of the prostate
- Documented metastatic prostate adenocarcinoma
- Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status <= 2
Key exclusion criteria (5 listed)
- Prior chemotherapy, except estramustine
- Prior chemotherapy with docetaxel
- Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)
- One or more contraindications to the use of corticosteroids
- History of cancer-related hypercalcemia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| calcitriol | Drug | – |
| docetaxel | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study was stopped early (reason given: DSMB). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2007.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Howard I. Scher, MD study chair
Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center
Kim N. Chi, M.D. study chair
British Columbia Cancer Agency - Vancouver Centre
Ronald De-Wit, M.D. study chair
Erasmus University Medical Center (Netherlands)
222 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing calcitriol and docetaxel in people with Prostate Cancer, run by Novacea at 222 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 6 Nov 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 222 sites in United States, Germany, Canada, Romania, Hungary and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: DSMB). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2007.